2024 include, among other items: (i) intangible asset impairment charges of $
3.3
billion recorded in
Other (income)/deductions––net
,
(ii)
restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $
2.2
billion (primarily
recorded in
Restructuring charges and certain acquisition-related co
sts), (iii) actuarial valuation and other postretirement plan losses of $
579
million recorded in
Other (income)/deductions––net
, (iv) charges for certain legal matters of $
567
million recorded in
Other (income)/deductions––net,
and (v) a charge in
Other (income)/deductions––net
of $
420
million related to the expected sale of
one
of our facilities resulting from the discontinuation of our DMD program, partially offset by (vi) net gains on equity securities of $
1.0
billion and (vii) net gains of $
825
million on the partial sales of our investment in Haleon in March and October 2024, which are comprised of (a) total gains on the sales of $
945
million less (b) $
120
million in the fourth quarter (included in Other business activities) representing our pro-rata share of Haleon’s third quarter 2024 adjusted income recorded on a one quarter lag and implicitly included in the gain on the sale of those shares.
Earnings in 2023 included, among other items: (i) intangible asset impairment charges of $
3.0
billion recorded in
Other (income)/deductions––net
and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $
2.2
billion ($
290
million recorded in
Selling, informational and administrative expenses
and the remaining amount primarily
recorded in
Restructuring charges and certain acquisition-related co
sts), partially offset by (iii) net gains on equity securities of $
1.6
billion recorded in
Other (income)/deductions––net
. Earnings in 2022 included, among other items: (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $
1.4
billion ($
562
million recorded in
Selling, informational and administrative expenses
and the remaining amount primarily recorded in
Restructuring charges and certain acquisition-related costs
) and (ii) net losses on equity securities of $
1.3
billion recorded in
Other (income)/deductions––net
. See
Notes 3
and
4
.
B.
Geographic Information
Revenues exceeded $500 million in each of
11
,
14
and
24
countries outside the U.S. in 2024, 2023 and 2022, respectively. The U.S. is the only country to contribute more than
10
% of total revenue in 2024, 2023 and 2022. As a percentage of
Total revenues
, China was our largest market outside the U.S. (representing
4
% of total revenues) in 2024, and Japan was our largest market outside the U.S. in 2023 and 2022 (representing
6
% and
8
% of total revenues, respectively).
C.
Other Revenue Information
Significant Customers
We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of Comirnaty